Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

Yazar: Pal, Sumanta Kumar, Figlin, Robert A.
Baskı/Yayın Bilgisi 2010

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

Yazar: Pal, Sumanta Kumar, Figlin, Robert A.
Baskı/Yayın Bilgisi 2011

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy

Yazar: Banerjee, Natasha, Sachdev, Esha, Figlin, Robert A
Yayımlandı Cureus (2016)

Deciphering the anticancer mechanisms of sunitinib

Yazar: Pal, Sumanta Kumar, Figlin, Robert A, Yu, Hua
Baskı/Yayın Bilgisi 2010

Targeted Therapies for Non-Small Lung Cancer: An Evolving Landscape

Yazar: Pal, Sumanta Kumar, Figlin, Robert A., Reckamp, Karen
Baskı/Yayın Bilgisi 2010

A New Age for Vaccine Therapy in Renal Cell Carcinoma

Yazar: Pal, Sumanta K., Hu, Adriana, Figlin, Robert A.
Baskı/Yayın Bilgisi 2013

Renal cell carcinoma: An update for the practicing urologist

Yazar: Pal, Sumanta K., Bergerot, Paulo, Figlin, Robert A.
Yayımlandı Asian J Urol (2015)

Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer

Yazar: Reed, Jarred P., Devkota, Suzanne, Figlin, Robert A.
Yayımlandı Ann Transl Med (2019)

Renal cell carcinoma molecular targets and clinical applications, second edition /

Yazar: Bukowski, Ronald M., Figlin, Robert A., Motzer, Robert J.
Baskı/Yayın Bilgisi 2009

Renal cell carcinoma translational biology, personalized medicine, and novel therapeutic targets /

Yazar: Figlin, Robert A., Rathmell, W. Kimryn., Rini, Brian I.
Baskı/Yayın Bilgisi 2012

Chemokines as therapeutic targets in renal cell carcinoma

Yazar: Reckamp, Karen L, Strieter, Robert M, Figlin, Robert A
Baskı/Yayın Bilgisi 2008

Tivozanib: Current status and future directions in the treatment of solid tumors

Yazar: Pal, Sumanta K., Bergerot, Paulo G., Figlin, Robert A.
Baskı/Yayın Bilgisi 2012

Surveillance Strategies for Renal Cell Carcinoma Patients Following Nephrectomy

Yazar: Chin, Arnold I, Lam, John S, Figlin, Robert A, Belldegrun, Arie S
Baskı/Yayın Bilgisi 2006

Akt inhibitors in clinical development for the treatment of cancer

Yazar: Kumar Pal, Sumanta, Reckamp, Karen, Yu, Hua, Figlin, Robert A.
Baskı/Yayın Bilgisi 2010

Breaking through a plateau in renal cell carcinoma therapeutics: Development and incorporation of biomarkers

Yazar: Pal, Sumanta Kumar, Kortylewski, Marcin, Yu, Hua, Figlin, Robert A.
Baskı/Yayın Bilgisi 2010

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma

Yazar: Motzer, Robert J., Escudier, Bernard, Gannon, Andrew, Figlin, Robert A.
Yayımlandı Oncologist (2016)

Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults

Yazar: Pal, Sumanta K., Vanderwalde, Ari, Hurria, Arti, Figlin, Robert A.
Yayımlandı Drugs Aging (2011)

STAT3: A Target to Enhance Antitumor Immune Response

Yazar: Lee, Heehyoung, Pal, Sumanta Kumar, Reckamp, Karen, Figlin, Robert A., Yu, Hua
Baskı/Yayın Bilgisi 2011

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

Yazar: Zhang, Hao, Berel, Dror, Wang, Yanping, Li, Ping, Bhowmick, Neil A., Figlin, Robert A., Kim, Hyung L.
Baskı/Yayın Bilgisi 2013

CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer

Yazar: Reckamp, Karen L, Figlin, Robert A, Burdick, Marie D, Dubinett, Steven M, Elashoff, Robert M, Strieter, Robert M
Baskı/Yayın Bilgisi 2009